Hydroxychloroquine Market

Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.2 Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects.6 Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.7It is taken by mouth.[2] It is also being used as an experimental treatment for coronavirus disease 2019 (COVID-19).

Hydroxychloroquine Market contains market size and forecasts of Hydroxychloroquine (Plaquenil) in global, including the following market information:

Global Hydroxychloroquine (Plaquenil) Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Hydroxychloroquine (Plaquenil) Market Sales, 2017-2022, 2023-2028, (M Pcs)

Global top five Hydroxychloroquine (Plaquenil) companies in 2021 (%)

The global Hydroxychloroquine (Plaquenil) market was valued at 58 million in 2021 and is projected to reach US$ 103.7 million by 2028, at a CAGR of 8.7% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

100mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hydroxychloroquine (Plaquenil) include Sanofi, Actavis (TEVA ), Mylan, Novartis, Covis Pharmaceutical, Cardinal Health, Apotex Corporation, Hikma Pharmaceuticals and Aphena Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Hydroxychloroquine (Plaquenil) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hydroxychloroquine (Plaquenil) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Hydroxychloroquine (Plaquenil) Market Segment Percentages, by Type, 2021 (%)

100mg

200mg

Other

Global Hydroxychloroquine (Plaquenil) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Hydroxychloroquine (Plaquenil) Market Segment Percentages, by Application, 2021 (%)

Lupus Erythematosus

Rheumatoid Arthritis

COVID-19

Others

Global Hydroxychloroquine (Plaquenil) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Pcs)

Global Hydroxychloroquine (Plaquenil) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hydroxychloroquine (Plaquenil) revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Hydroxychloroquine (Plaquenil) revenues share in global market, 2021 (%)

Key companies Hydroxychloroquine (Plaquenil) sales in global market, 2017-2022 (Estimated), (M Pcs)

Key companies Hydroxychloroquine (Plaquenil) sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Sanofi

Actavis (TEVA )

Mylan

Novartis

Covis Pharmaceutical

Cardinal Health

Apotex Corporation

Hikma Pharmaceuticals

Aphena Pharma

Concordia Healthcare

AvKARE (Amneal Pharmaceuticals)

Ipca Laboratories

Shanghai Pharmaceuticals Holding

Taj Pharmaceuticals

Cinkate Corporation

Cadila Healthcare

Sun Pharma

Zydus Cadila

Advanz Pharma

Bristol Laboratories

Hanlim Pharmaceutical

Kyung Poong